๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wuhan
Clinical trial register · China

Clinical Trials in Wuhan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 44 Guangzhou 29 Shanghai 25 Tianjin 22 Hangzhou 20
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing44 Guangzhou29 Shanghai25 Tianjin22 Hangzhou20
All 57 locations
Target enrolment
to

Trials with a site in Wuhan

16 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253Multiple Myeloma
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Not yet open
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
NCT06580223Multiple Myeloma, Venous Thromboembolism
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
530
Wuhan
2025-09-01
Active, closed
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT06934044Multiple Myeloma
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
NCT07028970Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Recruiting
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
NCT06503107Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
60
Wuhan
2024-04-23
Recruiting
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
NCT06228794Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
458
Wuhan
2024-04-01
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
NCT06140966Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
54
Wuhan
2023-10-20
Recruiting
Helical Tomotherapy in Multiple Myeloma
NCT05970198Multiple Myeloma
Fuling Zhou
Not applicable
58
Wuhan
2023-06-14
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
By invitation
AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
NCT07410403Multiple Myeloma
Fuling Zhou
Observational
10
Wuhan
2018-08-01
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/wuhan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Wuhan that also match the filters currently applied.

How many clinical trials are recruiting in Wuhan?

10 of the 16 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Wuhan), 16 studies
PhaseStudiesRecruitingShare
Phase 35231.3%
Observational4325%
Phase 1/23318.8%
Not applicable2112.5%
Phase 1106.3%
Phase 2116.3%

Most active sponsors

Lead sponsors with the most studies (Wuhan)
Lead sponsorStudiesRecruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology43
AbbVie20
Fuling Zhou21
Pfizer22
Donghua Zhang10
Gracell Biotechnologies (Shanghai) Co., Ltd.11
Hoffmann-La Roche10
Innovent Biologics (Suzhou) Co. Ltd.11
Nanjing IASO Biotechnology Co., Ltd.11
Shanghai Zhongshan Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.